FUE Hair Transplant Statistics 2024: AlviArmani Case Analysis

FUE Hair Transplant Statistics 2024 — AlviArmani U.S. Case Analysis

Precision and artistry in motion — data that defined a pivotal year.

See how 2025 built on these results → View 2025 Case Insights
“2024 was the year AlviArmani redefined scale — proving that precision and density could grow together. Every procedure reflected our commitment to natural design and reproducible outcomes.”

— Ashkan Hayatdavoudi, MD, ESQ — Operating Director, AlviArmani

2024 U.S. Case Overview

Data showed a balanced case mix with continued national growth and steady increases in higher-density sessions.

Median 2,500 Mode 3,000 Avg. grafts ≈ 2,210

2024 Highlights at a Glance

Metric2024 PerformanceNotes
Average Grafts per Case≈ 2,210Based on 2024 cases with numeric graft counts
Median / Mode Graft Range2,500 (median) / 3,000 (mode)Balanced mix across mid-range graft bands
Maximus-Level Procedures (>3,000 grafts)≈ 19.3%Established early high-density precedent
≥ 4,000-Graft Sessions≈ 0.8%Highest observed case: 4,000 grafts
Overall Case Mix (2024)<2000: 23.2% · 2000–2499: 16.3% · 2500–2999: 20.9% · 3000–3499: 20.3% · ≥3500: 19.3%More distributed case structure before high-density expansion

Technique Landscape

2024 marked a pivotal shift in procedural adoption — with No-Shave FUE becoming a patient favorite and the Privé™ experience emerging as the ultimate high-touch model for privacy and comfort. These approaches redefined the standard for aesthetic restoration without downtime.

2024 Procedure Type Mix (Share of Total U.S. Cases)
2024 Procedure Mix Vitruvian FUE — 66.7% Maximus (>3,000 grafts) — 19.3% Executive No‑Shave™ — 12.0% Privé™ — 2.0% Maximus share computed as >3,000 grafts across all 2024 U.S. cases with numeric counts. Remaining share attributed to Vitruvian FUE.

Travel Patterns: National Patient Base

  • Beverly Hills: 44% of patients came from out of town, underscoring its continued draw as a national and international destination for high-density FUE artistry.
  • Salt Lake City: 36% of patients were out of state — signaling strong regional momentum from Idaho, Colorado, and neighboring markets.
  • Combined out-of-town share: ~41% of all U.S. patients — confirming AlviArmani’s nationwide reach and early balance between destination and regional care models.
Patients Traveling from Out of State — 2024
Beverly Hills — 44% Salt Lake City — 36%

Method: patient State compared to clinic’s local territory; blanks counted as in-state. Data verified against 2024 local vs. out-of-town analysis.

Consult-to-Procedure Velocity

In 2024, lead-to-procedure time averaged 61 days with a median of 52 days. These figures formed the operational baseline for efficiency improvements observed in subsequent years.

Median Days from Consultation to Procedure — 2024
52 days

Baseline year establishing future velocity comparisons. Derived from confirmed consult and booking data.

Conclusion

2024 represented both growth and refinement. It marked the transition from a single-site prestige model to a scalable, bi-regional network grounded in design continuity, patient trust, and operational precision — setting a new national standard for natural, high-density restoration.

Last reconciled: October 28, 2025

Related Reading